FDA New Drug Application (NDA): Requirements and Process

The New Drug Application is the formal mechanism through which a pharmaceutical sponsor requests FDA authorization to market a new drug product in the United States. Governed primarily by 21 C.F.R. Part 314, the NDA process requires sponsors to demonstrate that a drug is safe and effective for its proposed use, that the proposed labeling is accurate, and that manufacturing methods meet applicable quality standards. Understanding NDA requirements is essential for sponsors, regulators, and healthcare professionals who navigate the boundary between clinical development and commercial approval.

• Definition and scope
• Core mechanics or structure
• Causal relationships or drivers
• Classification boundaries
• Tradeoffs and tensions
• Common misconceptions
• Checklist or steps (non-advisory)
• Reference table or matrix

Definition and scope

The NDA is the regulatory gateway for any sponsor seeking to introduce a new chemical or molecular entity — or a new formulation, dosage form, route of administration, or indication of an existing drug — into U.S. commerce. The statutory authority rests in Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355), which prohibits the introduction of a new drug into interstate commerce without an approved application.

The scope of an NDA encompasses the full evidentiary record assembled during drug development: preclinical pharmacology and toxicology data, Phase 1 through Phase 3 clinical trial results, proposed labeling, manufacturing process descriptions, and post-marketing commitment proposals where required. The FDA's Center for Drug Evaluation and Research (CDER) is the primary reviewing body for most NDA submissions, with the Center for Biologics Evaluation and Research (CBER) handling certain biological drug products that may follow a Biologics License Application pathway instead.

An NDA is distinct from an Investigational New Drug (IND) application, which authorizes clinical testing but does not permit marketing. It is also distinct from an Abbreviated New Drug Application (ANDA), which is the pathway for generic drugs that demonstrate bioequivalence to an approved reference listed drug — a separate process detailed at FDA Generic Drug Approval.

Core mechanics or structure

An NDA is organized according to the Common Technical Document (CTD) format, an internationally harmonized structure developed through the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The CTD comprises five modules:

• Module 1: Administrative and prescribing information (region-specific; includes proposed labeling and application forms)
• Module 2: Summaries and overviews covering quality, nonclinical, and clinical data
• Module 3: Quality documentation — chemistry, manufacturing, and controls (CMC)
• Module 4: Nonclinical study reports (pharmacology, toxicology, pharmacokinetics)
• Module 5: Clinical study reports (all phases)

The FDA conducts a 60-day filing review after submission to determine whether the application is sufficiently complete to warrant substantive review. If the application passes filing review, CDER assigns it a PDUFA goal date — the target action date under the Prescription Drug User Fee Act. The standard PDUFA review goal is 10 months from the date of filing for standard applications and 6 months for priority-designated applications (FDA PDUFA Commitments).

User fees collected under PDUFA fund a substantial portion of CDER's drug review operations. For fiscal year 2024, the application fee for an NDA requiring clinical data was set at $4,048,640 (FDA FY2024 PDUFA Fee Schedule).

Causal relationships or drivers

The evidentiary requirements of an NDA trace directly to failures in pre-1962 drug regulation. The Kefauver-Harris Drug Amendments of 1962 added the efficacy requirement to U.S. law after the thalidomide crisis demonstrated that pre-market review focused solely on safety was insufficient. Before 1962, sponsors needed only to show safety; after the amendment, substantial evidence of effectiveness — typically derived from adequate and well-controlled clinical investigations — became a mandatory threshold.

The size and complexity of modern NDAs are driven by four reinforcing factors:

1. Statistical rigor requirements: FDA guidance documents, including those harmonized through ICH E9 on statistical principles, require that pivotal trials be powered to detect clinically meaningful differences with defined Type I and Type II error rates.
2. Global harmonization: ICH M4 guidelines standardized the CTD format, reducing the burden on sponsors filing in multiple jurisdictions while simultaneously raising documentation depth expectations.
3. PDUFA-driven timelines: User fee agreements between FDA and industry have compressed review timelines, which in turn pressure sponsors to submit more complete applications to avoid refuse-to-file actions or complete response letters.
4. Manufacturing accountability: FDA's emphasis on pharmaceutical quality systems and Good Manufacturing Practices means that CMC sections require process validation data, stability studies, and detailed facility information that can alone constitute thousands of pages.

Classification boundaries

NDAs exist within a larger system of application types defined by Section 505 of the FD&C Act. Understanding which subsection applies determines the evidentiary pathway and competitive protections available:

• 505(b)(1): The full NDA. The sponsor conducts and owns all clinical investigations supporting safety and effectiveness. Eligible for 5 years of new chemical entity (NCE) exclusivity if the active moiety has never been approved by FDA.
• 505(b)(2): A hybrid application. The sponsor relies at least partially on published literature or FDA's findings of safety and effectiveness for a previously approved drug. Commonly used for new formulations, new dosage forms, new routes, or new indications. Eligible for 3 years of exclusivity when the application contains new clinical investigations essential to approval.
• 505(j): The ANDA pathway for generics, which is not technically an NDA but is part of the same statutory framework. Generics must demonstrate bioequivalence rather than independent clinical efficacy.

The distinction between 505(b)(1) and 505(b)(2) has significant commercial implications. A 505(b)(2) sponsor may reference the Agency's prior approval findings, reducing development costs, but must address any listed patents covering the reference drug through Paragraph IV certification if seeking approval before patent expiration — a process that can trigger 30-month stays and patent litigation.

The NDA also intersects with the FDA Accelerated Approval Pathways framework, under which certain drugs for serious conditions may receive approval based on a surrogate endpoint reasonably likely to predict clinical benefit, with post-marketing confirmatory trial requirements attached.

Tradeoffs and tensions

Speed versus completeness: PDUFA timelines create pressure on both sponsors and reviewers. A sponsor that submits an incomplete application risks a refuse-to-file determination, resetting the clock. A sponsor that delays submission to achieve completeness loses market time. The complete response letter (CRL) — issued when FDA cannot approve an application as submitted — represents a formal mechanism for managing this tension, but a CRL can add 12 to 24 months to a product's timeline.

Surrogate endpoints versus clinical outcomes: Accelerated approval based on surrogate endpoints allows faster patient access but introduces uncertainty. FDA has historically issued withdrawal actions when confirmatory trials failed to verify clinical benefit, as seen in the oncology space following the 2021 Oncology Center of Excellence accelerated approval re-evaluation initiative.

Exclusivity versus access: NCE exclusivity and pediatric exclusivity (an additional 6 months granted for pediatric studies under the Best Pharmaceuticals for Children Act) delay generic entry, sustaining innovation incentives for manufacturers while extending the period of higher-priced branded access. This tradeoff is a persistent point of tension in pharmaceutical policy debates before Congress.

Patent and regulatory exclusivity misalignment: Patent protection and FDA exclusivity operate on different legal tracks. A drug can have expired patents but active regulatory exclusivity, or vice versa. Sponsors and generic entrants must analyze both tracks independently.

Common misconceptions

Misconception: FDA approval guarantees a drug is entirely risk-free.
Correction: FDA applies a benefit-risk framework. Approval means the demonstrated benefits outweigh known risks for the indicated population under the proposed labeling conditions. Post-marketing surveillance through FDA Adverse Event Reporting continues to characterize the safety profile after approval.

Misconception: A successful Phase 3 trial guarantees NDA approval.
Correction: Clinical efficacy is necessary but not sufficient. FDA can issue a CRL based on CMC deficiencies, manufacturing facility inspection findings, or labeling disputes even when clinical data are considered adequate. Approximately 17% of original NDAs received CRLs in fiscal years 2019–2022 based on FDA CDER annual performance data.

Misconception: The 505(b)(2) pathway is a shortcut that bypasses safety evaluation.
Correction: A 505(b)(2) applicant must still address the safety and effectiveness of any aspects of the product not covered by the referenced approval — including any new clinical studies required. FDA retains full authority to require additional data.

Misconception: NDA submission is the final step before marketing.
Correction: Even after approval, sponsors must comply with post-marketing requirements, which may include Risk Evaluation and Mitigation Strategies (REMS), required pediatric studies, and labeling updates as new safety information emerges.

Checklist or steps (non-advisory)

The following sequence reflects the formal stages of an NDA submission and review cycle as described in 21 C.F.R. Part 314 and FDA guidance documents:

1. Pre-IND meeting (optional but standard practice): Sponsor requests Type B meeting with CDER to align on development program before IND submission.
2. IND submission and clinical development: Phases 1, 2, and 3 trials conducted under active IND; end-of-Phase 2 meeting used to confirm Phase 3 design.
3. Pre-NDA meeting: Sponsor requests Type B meeting with review division to discuss submission format, content, and outstanding issues.
4. NDA assembly in CTD format: All five modules compiled, including proposed prescribing information, patent certifications, and user fee payment.
5. Electronic submission via FDA Electronic Submissions Gateway: Submission must comply with eCTD specifications per FDA eCTD guidance.
6. 60-day filing review: FDA determines whether application is complete enough for substantive review; refuse-to-file letter issued if deficient.
7. Substantive review: Primary reviewers assess clinical, CMC, pharmacology/toxicology, and statistical sections; labeling negotiations begin.
8. Pre-approval inspection (PAI): FDA inspects manufacturing facilities listed in the application.
9. Advisory Committee meeting (if applicable): FDA may convene an independent expert panel for novel or complex applications.
10. Action letter issued: FDA issues either an approval letter or a CRL by the PDUFA goal date.
11. Post-marketing compliance: Sponsor implements any REMS, fulfills post-marketing commitment studies, and maintains FDA Prescription Drug Labeling in accord with evolving safety information.

Reference table or matrix

The table below compares the three primary drug application types under Section 505 of the FD&C Act:

Sources: 21 U.S.C. § 355; FDA FY2024 PDUFA Fee Rates; FDA FY2024 GDUFA Fee Rates

Additional NDA-adjacent pathways — including the Biologics License Application and the FDA Orphan Drug Designation program — interact with but remain distinct from the standard NDA framework. The broader context of how FDA regulates the drug approval lifecycle from IND through post-market surveillance is covered at FDA Drug Approval Process, and the full landscape of FDA programs is accessible through the FDA Authority reference index.